Antioxidant enzymes
SOD2 · GPX1 · CAT · NQO1
The body's defence against reactive oxygen species works as a chain: superoxide is converted to hydrogen peroxide, which is then detoxified. Each step has a common functional variant. Together they describe how well cells buffer oxidative stress, but they are not a disease finding.
The four steps
rs4880 (SOD2, Ala16Val): mitochondrial manganese superoxide dismutase converts superoxide into H₂O₂. The variant sits in the mitochondrial targeting sequence; the Ala allele is imported efficiently and yields about 40 percent more active enzyme there, while the Val allele is partly arrested in the inner membrane and degraded (Sutton 2005). rs1050450 (GPX1, Pro198Leu): glutathione peroxidase 1 further breaks down H₂O₂; the Leu allele goes along with lower enzyme activity (Arsova-Sarafinovska 2008). rs1001179 (CAT, catalase): a direct H₂O₂ detoxifier; the effect allele lowers expression. rs1800566 (NQO1, Pro187Ser): protects against quinone toxicity; the T allele contributes substantially to population variation in enzyme activity, and homozygous carriers have very low residual activity (Lajin 2013).
What it means
These four enzymes form the built-in panel 'Antioxidant Enzymes' and together describe how well a cell buffers radicals. An unfavourable profile is not a disease finding but a pointer to higher oxidative stress pressure; it can explain why someone reacts more sensitively to loads such as smoking, intense exercise or environmental toxins. Blanket antioxidant supplementation cannot be derived from it.
Context
The functional effects of the individual variants are documented; their disease associations are inconsistent by population and should not be over-interpreted. Genome shows the markers as technical evidence.
What Genome measures. The genotypes at rs4880 (SOD2), rs1050450 (GPX1), rs1001179 (CAT) and rs1800566 (NQO1).
Related topics
Sources
- 1Sutton et al., 2005 The MnSOD Ala16Val dimorphism modulates mitochondrial import and mRNA stability. Pharmacogenetics and Genomics 15:311–319. doi.org/10.1097/01213011-200505000-00006
- 2Arsova-Sarafinovska et al., 2008 GPX1 genetic polymorphism, erythrocyte GPX activity and prostate cancer risk. International Urology and Nephrology 41:63–70. doi.org/10.1007/s11255-008-9407-y
- 3Lajin & Alachkar, 2013 The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a meta-analysis. British Journal of Cancer 109:1325–1337. doi.org/10.1038/bjc.2013.357